PureTech Health (NASDAQ:PRTC) Shares Down 6.7% – Should You Sell?

PureTech Health plc (NASDAQ:PRTC) shares dropped 6.7% during trading on Monday . The stock traded as low as $21.29 and last traded at $21.29. Approximately 943 shares were traded during trading, a decline of 77% from the average daily volume of 4,061 shares. The stock had previously closed at $22.82.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PRTC shares. Leerink Partnrs upgraded PureTech Health to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners began coverage on shares of PureTech Health in a research note on Monday, September 9th. They issued an “outperform” rating and a $45.00 price objective for the company.

PureTech Health Price Performance

The firm has a 50-day simple moving average of $20.41 and a 200 day simple moving average of $23.48.

Institutional Investors Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. AWM Investment Company Inc. acquired a new position in PureTech Health plc (NASDAQ:PRTC) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,900 shares of the company’s stock, valued at approximately $197,000. 0.04% of the stock is owned by institutional investors and hedge funds.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.